<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03999853</url>
  </required_header>
  <id_info>
    <org_study_id>BIOKIER PROTOCOL CL-301-00</org_study_id>
    <nct_id>NCT03999853</nct_id>
  </id_info>
  <brief_title>Butyrate Adjuvant Therapy for Type 1 Diabetes</brief_title>
  <official_title>Colonic Delivery of Butyrate to Improve Insulin Sensitivity and Lower Triglycerides in Type 1 Diabetes Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioKier Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are interested to evaluate the effect of BKR-017 (colon-targeted 500 mg
      butyrate tablets) as adjuvant therapy on metabolic control in type 1 diabetes (TID) subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test effect of BKR-017 (colon-targeted 500 mg butyrate tablets) as adjuvant
      therapy in type 1 diabetes (TID) Subjects on metabolic control in this population. Insulin
      sensitivity, glucose control (variability) and triglycerides will be measured after 8 weeks
      of treatment and compared to baseline.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>(Day 0) to Day 28 and Day 56</time_frame>
    <description>Change in Insulin sensitivity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose Variability and Triglycerides</measure>
    <time_frame>(Day 0) to Day 28 and Day 56</time_frame>
    <description>Changes in glucose measurements and triglycerides</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type1diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo / Butyrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will be receiving placebo for the first study period then 500 mg Butyrate tablets to be taken at a dose of 1.5 g (3 tablets) twice daily (BID) after washout and cross-over</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Butyrate / Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will be receiving 500 mg Butyrate tablets to be taken at a dose of 1.5 g (3 tablets) twice daily (BID) placebo for the first study period then placebo after washout and cross-over</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>BKR-017</intervention_name>
    <description>500 mg butyrate tablets</description>
    <arm_group_label>Butyrate / Placebo</arm_group_label>
    <arm_group_label>Placebo / Butyrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets that are identical in appearance to BKR-017</description>
    <arm_group_label>Butyrate / Placebo</arm_group_label>
    <arm_group_label>Placebo / Butyrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All type 1 diabetes with C-Peptide (CPR) less than 0.5 ng/mL subjects who are &gt; 20 and
             &lt;80 years of age recruited from the Mayo Clinic Endocrinology Clinic;

          2. Will also meet HbA1c level of 6.4-8.9% and BMI of &lt; 30 kg/m2 at week -4.

        Exclusion Criteria:

          1. Except for the use of insulin, no other treatments for T1D will be permitted.

          2. Pregnancy

          3. Inability or unwillingness of individual or legal guardian/representative to give
             written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Vella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paula Giesler, BSN</last_name>
    <phone>507-255-8345</phone>
    <email>Giesler.Paula@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vishakantha Murthy, PhD., MBA</last_name>
    <phone>507-255-8112</phone>
    <email>Murthy.Vishakantha@mayo.edu</email>
  </overall_contact_backup>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2019</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Adrian Vella</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>Butyrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

